Biosig Technologies (NASDAQ:STEX) Director Buys $17,160.00 in Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Director Morgan Lee Lekstrom acquired 5,500 shares of the business’s stock in a transaction dated Tuesday, January 27th. The stock was purchased at an average price of $3.12 per share, with a total value of $17,160.00. Following the acquisition, the director owned 76,500 shares of the company’s stock, valued at approximately $238,680. This trade represents a 7.75% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Monday, January 26th, Morgan Lee Lekstrom bought 23,000 shares of Biosig Technologies stock. The shares were purchased at an average cost of $3.30 per share, for a total transaction of $75,900.00.
• On Friday, January 23rd, Morgan Lee Lekstrom purchased 41,000 shares of Biosig Technologies stock. The stock was acquired at an average cost of $3.13 per share, with a total value of $128,330.00.

Biosig Technologies Trading Up 3.8%

Shares of NASDAQ:STEX traded up $0.13 during trading hours on Tuesday, hitting $3.53. 2,191,465 shares of the company’s stock traded hands, compared to its average volume of 1,288,933. The firm has a market cap of $524.59 million, a price-to-earnings ratio of -2.61 and a beta of 1.48. Biosig Technologies, Inc. has a 52 week low of $0.40 and a 52 week high of $14.11.

Biosig Technologies News Summary

Here are the key news stories impacting Biosig Technologies this week:

• Positive Sentiment: Company insiders have been buying material amounts of stock, signaling insider confidence: Director Morgan Lee Lekstrom purchased a series of lots (41,000 on Jan. 23; 23,000 on Jan. 26; and 5,500 on Jan. 27) at roughly $3.12–$3.30, bringing his ownership to 76,500 shares. Lekstrom Jan 23 SEC Filing Lekstrom Jan 26 SEC Filing
• Positive Sentiment: CIO Mitchell Young Williams acquired 51,511 shares (~$3.03 avg), increasing his stake to over 1 million shares — another significant insider buy that investors often view as a bullish signal. Williams SEC Filing
• Neutral Sentiment: A separate press release for “Streamex Corp. (NASDAQ: STEX)” announced the closing of a $35M public offering. That release appears tied to the same ticker symbol and could be creating ticker-driven volume/noise for STEX trades; relevance to Biosig’s fundamentals is unclear. Streamex $35M Offering
• Negative Sentiment: Recent analyst coverage is mixed-to-negative: Weiss Ratings began coverage with a “sell (D-)” assessment, and MarketBeat shows an average analyst view of “Sell” — this could cap upside if broader investor sentiment follows analysts. Weiss Ratings

Analyst Upgrades and Downgrades

Separately, Weiss Ratings assumed coverage on Biosig Technologies in a research note on Friday. They set a “sell (d-)” rating for the company. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.